Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

Supportive Care in Cancer

Volumn 20, Issue 5, 2012, Pages 909-921

  Peuvrel, L ^a   Bachmeyer, C ^b   Reguiai, Z ^c   Bachet, J B ^d   Andre T ^e   Bensadoun, R J ^f   Bouche O ^g   Ychou, M ^h   Dreno B ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CH Robert Debré ^*  (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g REIMS UNIVERSITY HOSPITAL   (France)

^h CENTRE VAL D AURELLE   (France)

Author keywords

EGFR inhibitors; Folliculitis; Hair changes; Paronychia; Skin toxicity; Xerosis

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ACNE; ACNE VULGARIS; ALOPECIA; AREA UNDER THE CURVE; CANCER RADIOTHERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG WITHDRAWAL; DRY SKIN; FOLLICULITIS; HAIR DISEASE; HISTOPATHOLOGY; HUMAN; HYPERTRICHOSIS; NAIL DISCOLORATION; NAIL DISEASE; NAIL LOSS; NAIL RIDGING; PARONYCHIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; PYOGENIC GRANULOMA; QUALITY OF LIFE; RADIATION DERMATITIS; REVIEW; ROSACEA; SKIN FISSURE; SKIN PAIN; SKIN PERMEABILITY; SKIN TOXICITY; SYMPTOM; TUMOR; XEROSIS;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG ERUPTIONS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 84863424046     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1404-0     Document Type: Review

References (59)

1. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23(22):5235-5246
2. Joshi SS, Ortiz S, Witherspoon JN, Rademaker A, West DP, Anderson R, Rosenbaum SE, Lacouture ME (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16):3916-3923
3. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3-4):152-159
4. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16(9):1425-1433
5. Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S (2009) Skin toxicities of targeted therapies. Eur J Cancer 45(Suppl 1):295-308
6. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J (2005) HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10(5):345-356
7. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491-500
8. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664
9. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 43(5):845-851
10. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55(4):657-670
11. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, Myskowski PL, Paul J, Perlis CS, Saltz L, Spencer S (2009) NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 7(Suppl 1):S5-S21, quiz S22-24
12. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151(1):238-241
13. Roe E, Garcia Muret MP, Marcuello E, Capdevila J, Pallares C, Alomar A (2006) Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 55(3):429-437
14. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13(13):3913-3921
15. Fernandez-Torres R, Martinez Gomez W, Cuevas Santos J, Paradela S, Fonseca Capdevila E (2010) Rosaceiform eruption induced by cetuximab. Eur J Dermatol 20(3):392-393
16. Nardone B, Nicholson K, Newman M, Guitart J, Gerami P, Talarico N, Yang XJ, Rademaker A, West DP, Lacouture ME (2010) Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 16(17):4452-4460
17. Krueger JG, McCarthy SP, Conlan MG, Iwata KK (2008) Characterization of skin pathology in non-small cell lung cancer patients treated with the EGFR tyrosine kinase inhibitor erlotinib. J Am Acad Dermatol 58(2 S2):AB33
18. Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature reviews 6(10):803-812
19. Wolf M, Swaisland H, Averbuch S (2004) Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 10 (14):4607-4613
20. Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG (2009) Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 115 (7):1544-1554
21. Van Cutsem E, Peeters M, Gelderblom H (2007) Cetuximab doseescalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). Ann Oncol 18S(suppl vii)(22), Abstract O-0034
22. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park, NY) 21(14):1696-1706, discussion 1706-1699, 1712, 1715
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132
24. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, HubermanM, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238-3247
25. Ouwerkerk J, Boers-Doets C (2010) Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 14(4):337-349
26. Jatoi A, Nguyen PL (2008) Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 13 (11):1201-1204
27. Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19(1):142-149
28. Bonner JA, Ang K (2007) More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 357(18):1872-1873, author reply 1873
29. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME (2009) Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115(6):1286-1299
30. Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 77(2):120-123
31. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345
32. Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M (2011) Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 74(1):98-102
33. Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A (2009) Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? Anti-cancer Drugs 20(10):856-866
34. Van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews 35(8):692-706
35. Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clinical Lung Cancer 9(1):59-60
36. Saurat JH (2009) Dermatologie et infections sexuellement transmissibles, 5eth edn. Masson, Issy-les-Moulineaux
37. Karthaus M, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J et al (2009) Epidermal growth factor receptor (EGFR) inhibitorrelated skin toxicity: review of interim data from a phase II study (2260314) of panitumumab with FOLFIRI in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(15S):e20364
38. Ocvirk J, Cencelj S (2010) Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 24(4):453-459
39. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C (2009) Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 161(3):515-521
40. Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D (2009) A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 39(5):321-326. doi:5
41. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, Derynck R (1995) Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376 (6538):337-341
42. Gerber PA, Buhren BA, Cevikbas F, Bolke E, Steinhoff M, Homey B (2010) Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 63(1):163-165
43. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56(2):317-326
44. Rigopoulos D, Larios G, Gregoriou S, Alevizos A (2008) Acute and chronic paronychia. Am Fam Physician 77(3):339-346
45. Lacouture ME, Lai SE (2006) The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 155(4):852-854
46. Piraccini BM, Bellavista S, Misciali C, Tosti A, de Berker D, Richert B (2010) Periungual and subungual pyogenic granuloma. Br J Dermatol 163(5):941-953
47. Melichar B, Nemcova I (2007) Eye complications of cetuximab therapy. Eur J Cancer Care 16(5):439-443
48. Springer K, Brown M, Stulberg DL (2003) Common hair loss disorders. Am Fam Physician 68(1):93-102
49. Donovan JC, Ghazarian DM, Shaw JC (2008) Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Archives of Dermatology 144(11):1524-1525
50. Hepper DM, Wu P, Anadkat MJ (2011) Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 64(5):996-998
51. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567-578
52. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610-621
53. Bossi P, Liberatoscioli C, Bergamini C, Locati LD, Fava S, Rinaldi G, Orlandi E, Olmi P, Tagliabue E, Menard S, Licitra L (2007) Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Ann Oncol 18 (3):601-602
54. Mitra SS, Simcock R (2006) Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24(16):e28-29
55. Gerber PA, Enderlein E, Homey B, Muller A, Boelke E, BudachW (2007) Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 25(29):4697-4698, author reply 4698-4699
56. (2006) CTCAE v3-0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm. Accessed 17 June 2011
57. (2009) CTCAE v4-0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm. Accessed 17 June 2011
58. Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L,Wagner L,West DP, Rapoport BL, KrisMG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509-522
59. Chan A, Tan EH (2010) How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 19 (10):1667-1774